What's in Fresenius Kabi SwissBioSim GmbH's pipeline?

Fresenius Kabi SwissBioSim GmbH has 8 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Fresenius Kabi SwissBioSim GmbH's portfolio?

Top competitors by shared drug class: Celltrion, Hoffmann-La Roche, Allergan, Armando Torres Ramírez, Assistance Publique - Hôpitaux de Paris.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fresenius-kabi-swissbiosim-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fresenius Kabi SwissBioSim GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fresenius Kabi SwissBioSim GmbH pipeline: 0 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
EU-Humira	EU-Humira	phase 3
FKS518	FKS518	phase 3	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)	Immunology
US-licensed Prolia (Amgen)	US-licensed Prolia (Amgen)	phase 3	Denosumab	RANKL	Osteoporosis
MSB11022	MSB11022	phase 3	Monoclonal antibody (biosimilar)	HER2 (human epidermal growth factor receptor 2)	Oncology
EU-approved RoActemra	EU-approved RoActemra	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6R (Interleukin-6 receptor)	Immunology
MSB11456	MSB11456	phase 3	Monoclonal antibody (biosimilar)	HER2 (human epidermal growth factor receptor 2)	Oncology

Therapeutic area mix

Immunology · 2
Oncology · 2
Osteoporosis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celltrion · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Allergan · 1 shared drug class
Armando Torres Ramírez · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma China, Inc. · 1 shared drug class
Astellas Pharma Europe Ltd. · 1 shared drug class
Andrew B Adams · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fresenius Kabi SwissBioSim GmbH:

Cite this brief

Drug Landscape (2026). Fresenius Kabi SwissBioSim GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fresenius-kabi-swissbiosim-gmbh. Accessed 2026-05-17.